Clinical UpdatePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Non-Hodgkin's Lymphoma: The Evolution of Therapy CME
Authors: R. Gregory Bociek, MD, MSc; James O. Armitage, MD
Disclosures

Release Date: June 23, 2003; Valid for credit through June 23, 2004

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.

Contents of This CME Activity
  1. Non-Hodgkin's Lymphoma: The Evolution of Therapy
    Introduction
    Classification of Disease
    Clinical Evaluation and Staging of Patients With NHL
    Prognostic Factors
    Treatment of NHL
    Toward New Treatment Strategies for NHL
    Unconjugated Monoclonal Antibodies
    Conjugated Monoclonal Antibodies (RIT)
    Monoclonal Antibodies in Conjunction With High-Dose Therapy/Autologous Stem-Cell Transplantation
    Nonmyeloablative Allogeneic Stem-Cell Transplantation (NAST)
    Summary and Future Directions
    References


 
Legal Disclaimer
The material presented here does not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity.
Copyright © 2003 Medscape.

 
Genentech-IDEC
  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.